KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Cash & Equivalents (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Cash & Equivalents for 17 consecutive years, with $3.6 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 7.76% year-over-year to $3.6 billion, compared with a TTM value of $3.6 billion through Dec 2025, up 7.76%, and an annual FY2025 reading of $3.6 billion, up 7.76% over the prior year.
  • Cash & Equivalents was $3.6 billion for Q4 2025 at Teva Pharmaceutical Industries, up from $2.2 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $3.6 billion in Q4 2025 and bottomed at $1.7 billion in Q1 2025.
  • Average Cash & Equivalents over 5 years is $2.5 billion, with a median of $2.2 billion recorded in 2022.
  • The sharpest move saw Cash & Equivalents surged 47.58% in 2024, then plummeted 43.26% in 2025.
  • Year by year, Cash & Equivalents stood at $2.2 billion in 2021, then rose by 29.38% to $2.8 billion in 2022, then increased by 15.17% to $3.2 billion in 2023, then rose by 2.29% to $3.3 billion in 2024, then increased by 7.76% to $3.6 billion in 2025.
  • Business Quant data shows Cash & Equivalents for TEVA at $3.6 billion in Q4 2025, $2.2 billion in Q3 2025, and $2.2 billion in Q2 2025.